RE:Citron Research to speak....Yeah..not good for shareholders. Left got a tick up in credibility today, giving the non compliance found at Philidor and the cutting ties from CVS and Express Scripts, and now Valeant. Now its the battle of Valuation (Ackman) vs Scrutiny/Investigation/further possible bad headlines/more short thesis. VRX with shared employees and optics of some control at Philidor has a lot explaining to do, and likely will share in the negative consequences around the Philidor issue. Ackman seems to be side stepping Philidor, implies the possible negatives are priced in. I suspect the negatives win out over valuation arguments for a little while yet. An issue is, even as Ackman said, this may take a lengthy time to play out. For VRX, time is an issue.